Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.12 USD | -0.43% | -0.03% | -19.96% |
May. 02 | Omnicell Shares Rise After Q1 Non-GAAP Earnings, Revenue Beat Estimates | MT |
May. 02 | Transcript : Omnicell, Inc., Q1 2024 Earnings Call, May 02, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- Low profitability weakens the company.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.96% | 1.38B | B | ||
+5.85% | 32.93B | C | ||
+20.16% | 7.94B | C- | ||
+30.81% | 4.19B | B- | ||
-25.95% | 2.8B | C- | ||
-31.87% | 1.17B | - | ||
+8.02% | 966M | C | ||
-35.73% | 900M | - | ||
-25.74% | 839M | - | C+ | |
-15.42% | 582M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- OMCL Stock
- Ratings Omnicell, Inc.